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Estrogens and estrogen mimics prevalent in aquatic 
environment are of great environmental concern because of their 
endocrine disrupting and carcinogenic activities. Looking to the 
wide variety of natural as well as structurally different synthetic 
estrogen mimics, a reliable in-vitro assay is required for screening 
the estrogenic activity of endocrine disrupting compounds 
(EDCs). Surface plasmon resonance (SPR) is one of the most 
promising analytical tools to monitor the high-performance 
biomolecular interactions in a label free, real time format. Present 
paper demonstrates a facile SPR based affinity bioassay 
employing estrogen receptor-α, human (hERα) functionalized self 
assembled monolayer covalently bound onto the gold sensor chip 
as recognition species. A successful interaction of potential 
estrogen mimics with estrogen receptor is evidenced by net rise in 
SPR angle. The assay has been validated in terms of optimum 
experimental conditions and specificity with estrogen as a positive 
control showing maximum estrogenic activity. As a proof of 
concept, proposed affinity assay is tested for screening the 
estrogenic activity of progesterone, pregnenolone, tamoxifen, and 
bisphenol-A as representative examples of potential EDCs of 
different classes.  
Keywords: Surface plasmon resonance, Label-free affinity, 
Biosensor, Estrogen receptor, Estrogenic activity, 
Estrogen mimics, Endocrine disrupting chemicals 
Endocrine-disrupting compounds (EDCs) are 
chemical substances of natural or synthetic origin 
prevalent in surface and waste-waters, are shown to 
block/ interfere with the production, metabolism 
and/or action of endogenous hormones posing threat 
to aquatic life, wild life and human health
1,2
. Naturally 
occurring estrogens and estrogen mimics (chemicals 
that antagonize the actions of estrogen) typically 
referred as having estrogenic activity, represent the 
most significant class of EDCs. Natural estrogens 
(e.g. estrone, estradiol, estriol and estetrol), natural 
androgens (e.g. testosterone, dihydrotestosterone and 
androstenedione), phytoestrogen (e.g. coumestrol, 
genistein), pharmaceuticals (e.g. 17α-ethynyl estradiol, 
contraceptive pill formulations), pesticides and 
industrial chemicals (e.g. Atrazine, 2,4-dichloro-
phenoxyacetic acid), polyaromatic hydrocarbons  
(e.g. benzo[a]pyrene), poly chlorinated compounds 
(e.g. PCBs, dioxins, furans) and alkylphenols  
(e.g. 4-nonylphenol) are some of the major 
contributors of estrogenic activity in the aquatic 
environment. Fluorescence immunoassay (FIA) and 
radio-immunoassay (RIA), liquid chromatography, 
gas chromatography-mass spectrometry (GC-MS) are 
conventional standard analytical techniques
3,4
 for 
detecting EDCs, however multistep sample 
preparation and elaborate instrumental setup pose 
them as unsuitable for rapid screening of estrogenic 
activity. In-vivo biological assays for EDCs
5
 
involving cell lines, rodent uterotrophic test and 
vitellogenin assay using medaka fish also require 
expertise in handling highly specialized laboratory 
protocols, long assay time and ethical clearance. In 
present era of point-of-care testing (POCT), sensors 
and biosensors are the most convenient in-vitro assay 
tool for field monitoring at or near point of care.  
The third/fourth generation sensors are self-
contained integrated devices, capable of providing 
specific quantitative or semi-quantitative analytical 
information using a biological recognition element. 
Inclusion of biological element (e.g. enzyme, 
antibody, receptors etc) to sensor surface adds 
inherent specificity whereas nano thin sensor film 
combined with advanced transducers and the 
processing power of modern microelectronics offer 
highly sensitive and specific analytical tools as  
nano-biosensor. Mozaz et al.
6
 have reviewed 
biosensor strategies for EDCs monitoring. The 
electrochemical biosensors
7
 are based on depletion in 
voltammetric current of mediator redox probe upon 
binding; whereas most optical biosensors employ 
fluorescent and /or nanoparticles as label
8
. Surface 
plasmon resonance (SPR) based biosensors represents 
label free, real time, highly sensitive device to 
monitor organics and bioorganic analytes involving 
single step biomolecular interaction using a variety of 
biorecognition elements viz. enzymes
9
, antibody
10,
 
and receptor
11
.  
NOTES 
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The concept of SPR introduced by Ritchie
12
 has led 
to the emergence of a versatile optical phenomenon of 
SPR. Briefly, SPR occurs when a plane-polarized 
light strikes a plasmonic metal film interface,  
under the conditions of total internal reflection.  
In thin (ca. 50 nm) plasmonic metal (ca. Au) layers, 
electrons behaves as free electron gas, the plasmon 
and the irradiated light can excite them as surface 
plasmon. Associated with the surface plasmon is an 
evanescent wave that probes local changes in the 
refractive index (RI) of the ambient medium as a 
result of specific biomolecular binding events as 
shown in Fig 1. A glass prism coupling configuration 
or recently introduced fibre-optic configuration can be 
used to obtain evanescent wave to excite the surface 
plasmon
13
.  
Review of literature revealed number of SPR based 
biosensor assay protocol for estrogens and estrogen 
mimics, Table 1 includes significant parameters. Most 
of the SPR based studies have employed EDC 
specific antibodies
14-20
 for their sensitive detection. 
Estrogen receptors (ER), estrogen response element 
(ERE), and DNA element with ERE has also been 
reported as recognition species under varied 
immobilization strategies for biosensor application in 
inhibitive assay detection format
21-25
. Estrogen, E2 
show strong binding to antibody, Ab-E2
22,26
 as well as 
to receptor, ER whereas, the estrogen mimics e.g 
diethylstilbestrol and bisphenol-A (BPA) do not bind 
to Ab-E2 instead bind to ER
21,22
 and antagonize the 
actions of estrogen in human body. Therefore, it is 
pertinent to look for affinity based detection for 
screening the estrogenic activity. 
Herein, we report a facile SPR based direct affinity 
assay employing estrogen receptor as recognition 
species for screening the estrogenic activity of some 
of the potential EDCs of different categories (Fig. 2). 
Progesterone (P4) and pregnenolone (P5) are 
endogenous steroidal hormones structurally similar to 
estrogen. Progesterone is a progestogen sex hormone 
and pregnenolone is a precursor/metabolic 
intermediate in the biosynthesis of most of the steroid 
hormones. Tamoxiphen (Tm) and BPA are  
non-steroidal estrogen mimics. Tamoxifen is a 
pharmaceutical drug, act as estrogen receptor agonist 
and BPA is an estrogenic chemical of industrial 
origin. The assay has been validated in terms of 
optimizing the experimental conditions for direct 
affinity assay with estradiol as positive control 
standard with maximum estrogenic activity. 
 
Materials and Method 
 
Instrumentation 
A glass prism based SPR system in Kretchmann 
optical configuration (Autolab Model SPRINGLE 
(Eco-Chemie, Utrecht, Netherlands) and circulator 
(Julabo, GmbH) was used for present study. 
Microscopic glass chips (refractive index 1.26 -1.38) 
with gold coating (48-50 nm) were used as sensor 
chips. A matching liquid (refractive index = 1.515) 
was used to fix the chip onto the prism.  
All experiments were carried out at 25 ºC and  
sample tubes were kept in mini fridge cooled 4-5 °C 
during assay.  
 
Chemicals, reagents and bio-reagents 
17--estradiol (E2), estrogen receptor-α, human 
(hERα) (E1528), progesterone (P4), pregnenolone 
(P5), bisphenol-A (BSA), tamoxifen (Tm), 11- 
mercaptoundecanoic acid (11-MUA), N- hydroxyl 
succinamide, (NHS), N-Ethyl-N′-(3-dimethylamino-
propyl) carbodiimide hydrochloride (EDC), bovine 
 
 
Fig. 1 ― Schematic illustrations: (a) SPR at metal-dielectric 
interface in a prism based Kretschmann configuration,  
(b) functionalized sensor surface before and after affinity binding, 
(c) SPR response as reflectivity curve and (d) sensogram. 
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serum albumin (BSA), ethanol amine (EA), pepsin, 
glycine and tris-buffer were procured from Sigma 
Aldrich, USA. All other reagents were of AR grade 
from Merck. Deionized water and HPLC grade 
solvents were used to prepare solutions. 
Phosphate buffer saline (PBS), pH 7.2 (0.01 M 
disodium hydrogen phosphate and 0.01 M potassium 
dihydrogen phosphate containing 0.8% NaCl and 
0.02% KCl) in deionized water, was used as carrier 
buffer. Pepsin solution (0.2 M) prepared in glycine–
HCl buffer (pH 2) was used as regeneration buffer.  
A stock solution of BSA (0.2 g /10 ml) was prepared 
in 0.01 M sodium acetate buffer (pH 4.5).  
 
ER-BSA conjugate 
Estrogen receptor-α human (ER) conjugate with 
bovine serum albumin (BSA) as a carrier protein was 
prepared in-house. Briefly, equal quantities of BSA 
Table ― 1 SPR based biosensors assay protocol for estrogens and estrogen mimics 
Recognition element for SPR sensor 
surface 
Target analyte SPR Assay mode Detection range  References 
Normorphine-BSA / Au 
vs. Ab-morphine 
Morphine Inhibitive Immuno assay 0.1 - 10 ng.mL−1  Miura et al.14 
MA-BSA / Au vs. Ab-MA MA Inhibition Immuno assay 0.1–1000 ng.mL−1 Sakai et al.15 
E3G-ovalbumin / Au  vs. AbE3G  E3G Inhibitive Immuno assay 10 to 150 ng.mL−1 Sesay et al.16 
BaP-BSA/ Au  vs. Ab-BaP BaP  Inhibitive Immuno assay 0.01 -2 ng.mL−1 Miura et al.17 
CA and 2-MEA mix SAM/ BaP/ Au 
 vs. Ab-BaP 
BaP Inhibitive Immunoassay 50 pg.mL−1 to 100 ng.mL−1 Gobi et al.18 
C11- and C16-alkanethiols mix SAM/ 
analyte/ Au vs. respective antibodies  
Atr, BaP, 2,4-D, 
4-NP 
Inhibitive Immunoassay 0.05 - 0.26 ng.mL−1 Dostalek et al.19 
C11- and C16- alkanethiols mixed 
SAM / Au vs.Ab-BPA 
BPA Inhibitive Immunoassay  0.14 ng.mL−1 Hegnerová et al.20 
 
E2-BSA conjugate/ CM5/Au  
vs. hER 
E2, DES Inhibitive Affinity assay 100 µg.mL−1 Pearson et al.21 
E2-BSA conjugate/ CM5/Au  
vs. Ab-E2 / hER 
E2, DES Inhibitive affinityassay  0.2 ng.mL−1 E2 Miyashita et al.22 
ERαLBD- αβ/I biotinylated peptide / 
CM5/Au vs. peptides 
E2, EE2, 4-NP, Tm Inhibitive affinity bioassay 20 ng.L−1 E2 Spina et al.23  
E2-17PeNH /CM5/Au  vs. hrERα E3, E2, DES, E1, Tm, 
BPA, 4NP, T, P4  
Inhibitive affinity bioassay   0.1– 1 µM  
No response for P4 
Usami et al.24 
SA dextran /DNA /biotinylated 
ERE/ ERα  vs. E2 
EDCs, E1,  
DHS, E2  
Inhibitive affinity bioassay  1nM for low responder  
10 nM to 100 nM  
for high responder  
Asano et al.25 
hERα- BSA/ 11-MUA/ gold surface  E2, P5, Tm, BPA, P4 Direct affinity bioassay  0.1 -10 μg.mL−1  
No response to P4 
Present study 
SPR: Surface plasmon resonance; hERα: Estrogen Receptor-α, human; Sp1: transcriptional factor; BSA: bovine serum albumin; OG: 
oligoethylene glycol; CA: Cysteamine; 2-MEA: 2-mercaptoethanol CMD: Carboxymethyalted Dextran; 11-MUA: 11-
mercaptoundecanoic acid; ERαLBD: Engineered Estrogen Receptor-α; ERE: estrogen response element; E1: Estrone; E2: Estradiol; E3: 
Estriol, EE2: ethinyl-estradiol; MA: Methamphetamine; E3G: estrone-3-glucuronide; DES: Diethylstilbestrol; BPA: bisphenol-A; Tm: 
Tamoxifen; BPF: bis(4-hydroxyphenyl) methane; Atr: Atrazine; BaP: benzo[a]pyrene; 2,4-D: 2,4-dichlorophenoxyacetic acid; 
MA: Methamphetamine; 4NP: 4-nonylphenol; P4: Progesterone; ; P5: pregnenolone; T: Testosterone; E2-17PeNH: aminated estradiol 
with a spacer molecule; estrogen response element (ERE), Streptavidine (SA), endocrine disrupting compounds (EDCs), LBD: ligand 
binding domain  
 
 
 
Fig. 2 ― Structure of Estradiol (E2), Progesterone (P4), Pregnenolone (P5), Tamoxifen (Tm) and Bisphenol-A (BPA) 
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(0.01 g), NHS (0.01 g), and EDC (0.01 g) were 
dissolved in 1 mL sodium acetate (0.01 M, pH 4.5); 
mixture was sonicated for 2 min in an ultrasonic bath 
maintained at low temperature. To the above residue, 
estrogen receptor (ER) as received was then added 
and mixture was again sonicated for 30 s and left 
incubated at RT for 2 h. The estrogen receptor-BSA 
conjugate (ER-BSA) was then dialyzed in PBS  
buffer followed by distilled water at low temperature 
(3–5 ºC). Finally, the product was lyophilized, 
designated as stock ER-BSA conjugate and stored at 
−20 ºC. Dilutions of stock ER-BSA conjugate were 
made with 0.01 M sodium acetate.  
 
Functionalization of SPR chip and assay procedure 
Clean SPR sensor chips were immersed in 1 mM 
11-MUA/ethanol for minimum 3 h to allow self 
assembled monolayer (SAM) formation, however best 
results were obtained with overnight immersion
10
. 
SAM immobilized gold chip was placed carefully 
onto the prism of the SPR instrument using a 
matching liquid. First, a buffer of low salt 
concentration (0.01 M sodium acetate) was injected 
over sensor chip to stabilize the SAM. The next step 
was in-situ activation of SAM by introducing 50 μL 
NHS–EDC reagent (1:1 aqueous solution of 100 mM 
NHS and 400 mM EDC) with interaction time of  
5 min, followed by functionalization of sensor  
surface by introducing 50 μL ER-BSA conjugate  
(100 µg.mL
-1
) and allowing interaction for 15 min. 
Next, blocking step was performed by introducing 
one shot of ethanolamine (1 M, pH 8). All injections 
of over sensor surface were of 50 μL and carrier 
buffer (PBS, pH 7.2) was flowed over sensor surface 
after each interaction throughout the SPR experiment. 
Estradiol (E2) was flown over SPR sensor chip to 
optimize the SPR conditions for direct affinity 
binding interaction of ER and E2. The affinity binding 
interaction of immobilized ER-BSA conjugate and 
antigen, E2 (association phase) was studied for 
different periods. An optimum time period of ~15 to 
20 min was found to be satisfactory to get a stable 
SPR signal for successful interaction and binding. 
Every association phase was followed by a brief flow 
of carrier buffer for 120 s to wash out the un-reacted 
species (dissociation phase). The effective rise at the 
end of dissociation phase with respect to the 
resonance angle at the initiation of association phase 
is correlated with the analyte concentration in direct 
affinity assay. The regeneration step, comprised a 
brief flow of 0.2 M pepsin solution (in glycine–HCl 
buffer, pH 2).  
 
Results and Discussion 
The estrogenic activity of EDCs depends upon 
their binding with estrogen receptor which may  
pose a disrupting effect on gene expression. For 
screening the estrogenic activity, it is envisaged to 
establish the extent of affinity of estrogen receptor 
with potential EDCs, therefore efforts are made to 
establish a SPR based direct affinity assay employing 
sensor chip functionalized with estrogen receptor as 
sensing element.  
To avoid non-specific adsorption/binding at the 
sensor and to provide covalent bonding sites  
to the ligand, a self-assembled monolayer of  
11-mercaptoundecanoic acid (11-MUA) acted as 
matrix for immobilization the sensing element. In 
SPR mode, a net rise of resonance angle by ~ 200 mº 
(milli degree) as compared to the bare gold chip 
signifies a good quality and stable matrix of SAM 
over the gold surface
10
. The strong affinity of gold for 
sulphur, results in a perfect orderly monolayer  
over the bare gold sensor chip. The in-situ activation 
of free carboxylic groups of SAM was achieved 
through carbodiimide chemistry by introducing  
EDC-NHS reagent. Homemade estrogen receptor-
BSA (ER-BSA) conjugate as ligand was immobilized 
onto the gold senor chip through strong covalent 
amide bond via primary amine group of BSA and 
activated carboxylic group of long chain thioic acid.  
Fig. 3a shows SPR response of different steps of 
estrogen receptor functionalized biosensor surface 
fabrication. The in-situ activation of SAM is evident 
with a net rise of resonance angle by ~120 m◦  
(Fig. 3a, Inj 2) SPR sensor surface immobilized with 
SAM. Step-wise ligand immobilization of ER-BSA 
conjugate was performed to ascertain optimum 
concentration to be used for one-step immobilization. 
For in-situ ligand immobilization, an optimized ER-
BSA conjugate concentration as 100 µg.mL
−1
 over the 
activated SAM and interaction time for 15 min was 
found appropriate for fabrication of biosensor in 
present study. A sharp rise of resonance angle ca.  
200 mº (Fig. 3a, Inj 4) indicates a stable fabrication of 
ER-BSA conjugate functionalized SPR sensor 
surface. Brief desorption of the loosely bound 
conjugate got stabilized with PBS flow (Fig. 3a,  
Inj 5), indicates that covalently bound estrogen 
receptor conjugate is highly stable on the MUA 
INDIAN J. CHEM., SEC A, MAY 2020 
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modified sensor surface. Subsequent introduction of 
ER-BSA conjugate shot revealed a rise of 10 mº only, 
which shows that sensor surface is fully covered with 
conjugated ligand. Deactivation of unbound esters at 
sensor surface was accomplished by introducing 1 M 
ethanolamine (pH 8). 
To evaluate the affinity of estradiol and to monitor 
the estrogenic activity potential estrogen mimics 
towards estrogen receptor, 1 µg.mL
-1
 each of 
estradiol, progesterone, pregnenolone, tamoxifen and 
bisphenol-A was introduced over SPR sensor chip 
(ER-BSA/11-MUA/Au) for an optimized time of  
15 min to undergo association phase. A brief flow of 
carrier buffer for 2 min was important to wash out the 
un-reacted species (dissociation phase). The net rise at 
the end of dissociation phase with respect to the 
resonance angle at initiation of association phase is an 
affirmative sign for affinity with ER. The 
regeneration step comprised a brief flow of pepsin 
solution to liberate the surface-bound Ab-E2, leaving 
the sensor surface active for next injection. The 
receptor conjugate bound to the sensor chip was 
removed to regenerate the biosensor surface for 
multiple and cost-effective analyses.  
Fig. 3b shows association phase showing affinity 
binding interaction of proposed biosensor with 
estradiol as positive control and potential EDCs 
chosen for present study. The strong affinity 
interaction of E2 for ER-BSA is clearly marked as 
rise of ~100 mº of SPR signal (Fig. 3b). The rise in 
SPR signal for E2 interaction at proposed sensor 
surface served as a mark of highest estrogenic activity 
(i.e. positive control). The progesterone (P4) 
introduction to biosensor surface did not bring any net 
rise in SPR angle (Fig. 3b) which shows that P4 did 
not bind effectively with estrogen receptor at sensor 
surface and gets washed away with the flow of PBS. 
The binding interaction of with pregnenolone, 
tamoxifen and bisphenol-A is evidenced in  
sensogram with a net rise of SPR angle ~55 mº,  
~35 mº and ~30 mº, respectively (Fig. 3b). On 
comparing the estrogenic activity of estrogen mimics 
at concentration level of 1 µg.mL
-1
 towards estrogen 
receptor with respect to estradiol as positive control, 
pregnenolone, tamoxifen and bisphenol-A are EDCs 
with high estrogenic activity whereas progesterone 
shows no estrogenic activity. Results are in 
concordance with reported estrogenic status
24,25
.  
The regeneration capability of the sensor platform  
and its adaptability to a portable SPR device makes 
this assay promising for screening the estrogenic 
activity for field applications.  
 
Conclusions 
The proposed SPR based affinity assay employing 
homemade estrogen receptor-BSA conjugate 
covalently bonded to a long chain thioic acid 
monolayer immobilized over gold sensor chip  
(ER-BSA/11-MUA/Au) is suitable for label free,  
in-vitro screening of estrogen activity of hormone 
mimics and potential endocrine disrupting chemicals. 
An optimum time period of 15 min was found to be 
satisfactory for interaction between immobilized 
receptor and estrogens (association phase) to get a 
stable SPR signal showing successful interaction and 
binding and 2 min to wash out the un-reacted species 
(dissociation phase). The presence of chemical with 
estrogenic activity is evidenced by the effective rise in 
SPR angle at the end of dissociation phase with 
respect to resonance angle at initiation of association 
phase. Further on comparing the SPR signal of 
 
 
Fig. 3 ― (a) SPR response of in-situ fabrication of affinity 
biosensor (ER-BSA/11-MUA/Au) [steps 2- activation by EDC-
NHS solution; step 4- immobilization of ER-BSA conjugate; step 
6- repeat of step 4; step 8- ethanolamine (EA); steps 3-, 5-, 7-, 9- 
PBS flow] and (b) Sensogram showing direct affinity interaction 
of 1 µg.mL-1 each of estradiol (E2), progesterone (P4), 
pregnenolone (P5), tamoxifen (Tm) and bisphenol-A (BPA).  
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hormone mimics with that of estradiol as positive 
control standard, degree of estrogen activity could be 
ascertained in a much simple, single step, real time, 
label free direct affinity assay protocol. The simplicity 
of proposed SPR based direct affinity interaction 
protocols for detection of estrogen and estrogen 
mimics has potential for possible transformation into 
futuristic fiber optics based SPR probes for on-site 
environmental monitoring. 
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